Functional assessment of HDL: Moving beyond static measures for risk assessment.
Rosenson
Robert S
RS
SUNY Downstate, Brooklyn, NY, USA. robert.rosenson@downstate.edu
D000577:Amides; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics / Q000517:prevention & control; D002784:Cholesterol / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects / Q000235:genetics; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D002986:Clinical Trials as Topic; D004952:Esters; D000069438:Ezetimibe; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D008049:Lipase / Q000502:physiology; D008075:Lipoproteins, HDL / Q000502:physiology*; D009525:Niacin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D013438:Sulfhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use
D000577:Amides; D000924:Anticholesteremic Agents; D001384:Azetidines; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004952:Esters; D007328:Insulin; D008075:Lipoproteins, HDL; D011804:Quinolines; D013438:Sulfhydryl Compounds; D009525:Niacin; C411602:dalcetrapib; C483909:torcetrapib; D002784:Cholesterol; C410382:LIPG protein, human; D008049:Lipase; D000069438:Ezetimibe; D005947:Glucose